Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ventana Biotech, Inc. (VNTA)
Denver, CH
Ventana Biotech, Inc. is an emerging biotechnology enterprise focused on the lifecycle of drug candidates for personalized medicine, encompassing the identification, assessment, acquisition, development, and eventual commercialization through partnerships of relevant intellectual property. The company's primary therapeutic area is addressing obesity and its associated medical conditions. Notably, Ventana holds proprietary rights to a medicated chewing gum formulation that integrates an extract of hoodia gordonii and 2-hydroxyoleic acid. This unique composition is intended for the management of obesity, hypertension, and various other metabolic disorders. Ventana is actively engaged in developing these appetite-suppressant chewing gums into distinct products: a lower-dosage version aimed at the over-the-counter market, and a higher-dosage variant slated for distribution via pharmacists. The lower-strength product is expected to be retailed in drugstores and health food establishments. Established in 1989, Ventana Biotech, Inc. operates from Butschwil, Switzerland. The company adopted its current name in October 2008, having previously been known as Personalica, Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Shell Companies: +20.6%+29.9% ★ Q4'25: +5,865.1% (vs Q4'24)
-
EPS growth Shell Companies: -12.3%+33.3% ★ Q4'25: +700.0% (vs Q4'24)
-
FCF margin FCF growth · Shell Companies: +8.7%+48.1% ★ Q4'25: +3.5% (vs Q4'24)
-
EBIT margin Shell Companies: +0.0%+50.3% ★ Q4'25: +97.7% (vs Q4'24)
-
ROIC Shell Companies: +0.0%— Q4'25: -6,559.2% (vs Q4'24)
-
Share dilution Shell Companies: -10.2%+0.0% ★ Q4'25: +0.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Shell Companies: 0.00×5.27× Q4'25: 0.61× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Holsworth | Chief Operating Officer, Vice President and Executive Director | — | male |
| Elliott Martin | Vice President of Sales and Marketing | — | male |
| Janne Christensen | Chief Executive Officer, President, Chief Financial Officer, Treasurer and Director | — | female |
| Marilyn Thom | Vice President of Administration & Human Resources | — | female |
| Trevor Conn | Executive Director | — | male |
| Yoon Youngkeun | Secretary and Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VNTA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
